X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES SUN PHARMA SUVEN LIFESCIENCES/
SUN PHARMA
 
P/E (TTM) x 18.8 32.7 57.4% View Chart
P/BV x 3.7 2.7 134.2% View Chart
Dividend Yield % 0.6 0.5 134.7%  

Financials

 SUVEN LIFESCIENCES   SUN PHARMA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-18
SUN PHARMA
Mar-18
SUVEN LIFESCIENCES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs251701 35.8%   
Low Rs155433 35.8%   
Sales per share (Unadj.) Rs49.1110.4 44.5%  
Earnings per share (Unadj.) Rs9.711.0 88.5%  
Cash flow per share (Unadj.) Rs11.417.2 66.1%  
Dividends per share (Unadj.) Rs1.502.00 75.0%  
Dividend yield (eoy) %0.70.4 209.5%  
Book value per share (Unadj.) Rs60.3158.8 38.0%  
Shares outstanding (eoy) m127.282,399.26 5.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.15.1 80.4%   
Avg P/E ratio x20.951.6 40.4%  
P/CF ratio (eoy) x17.832.9 54.1%  
Price / Book Value ratio x3.43.6 94.3%  
Dividend payout %15.418.2 84.7%   
Avg Mkt Cap Rs m25,8251,360,021 1.9%   
No. of employees `0001.117.8 6.0%   
Total wages/salary Rs m61353,671 1.1%   
Avg. sales/employee Rs Th5,832.614,890.9 39.2%   
Avg. wages/employee Rs Th571.53,017.1 18.9%   
Avg. net profit/employee Rs Th1,153.81,480.6 77.9%   
INCOME DATA
Net Sales Rs m6,253264,895 2.4%  
Other income Rs m2338,388 2.8%   
Total revenues Rs m6,485273,282 2.4%   
Gross profit Rs m1,98256,081 3.5%  
Depreciation Rs m21314,998 1.4%   
Interest Rs m465,176 0.9%   
Profit before tax Rs m1,95544,295 4.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m7188,452 8.5%   
Profit after tax Rs m1,23726,338 4.7%  
Gross profit margin %31.721.2 149.7%  
Effective tax rate %36.719.1 192.5%   
Net profit margin %19.89.9 199.0%  
BALANCE SHEET DATA
Current assets Rs m5,622316,359 1.8%   
Current liabilities Rs m1,168198,643 0.6%   
Net working cap to sales %71.244.4 160.3%  
Current ratio x4.81.6 302.4%  
Inventory Days Days8195 85.9%  
Debtors Days Days36108 33.4%  
Net fixed assets Rs m3,325213,178 1.6%   
Share capital Rs m1272,399 5.3%   
"Free" reserves Rs m7,547378,606 2.0%   
Net worth Rs m7,674381,006 2.0%   
Long term debt Rs m1417,721 0.1%   
Total assets Rs m9,135643,028 1.4%  
Interest coverage x43.29.6 452.2%   
Debt to equity ratio x00 3.9%  
Sales to assets ratio x0.70.4 166.1%   
Return on assets %14.04.9 286.6%  
Return on equity %16.16.9 233.2%  
Return on capital %26.010.0 259.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,06640,816 12.4%   
Fx outflow Rs m2,00130,143 6.6%   
Net fx Rs m3,06510,673 28.7%   
CASH FLOW
From Operations Rs m69939,072 1.8%  
From Investments Rs m-6-33,708 0.0%  
From Financial Activity Rs m-577-15,393 3.7%  
Net Cashflow Rs m116-7,359 -1.6%  

Share Holding

Indian Promoters % 63.4 63.7 99.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 5.1 -  
FIIs % 0.0 23.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 8.3 439.8%  
Shareholders   37,287 133,026 28.0%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   CADILA HEALTHCARE  TTK HEALTHCARE  PROCTER & GAMBLE HEALTH  BIOCON   J.B.CHEMICALS  

Compare SUVEN LIFESCIENCES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 234 Points Higher; Healthcare and Realty Stocks Rally(Closing)

After opening the day on a flat note, Indian share markets witnessed buying interest during closing hours and ended higher.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

I Believe this is the Best Stock to Buy Today(Profit Hunter)

Jul 3, 2019

The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jul 16, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES - STRIDES PHARMA SCIENCE COMPARISON

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS